A phase II study of extended-field proton therapy alone after with or without endoscopic submucosal dissection for patients with superficial esophageal cancer

Not Applicable

Recruiting

• Conditions: Neoplasms

• Registration Number: KCT0004853
• Lead Sponsor: ational Cancer Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 21 April 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 77

Inclusion Criteria

histologically proven thoracic or gastroesophageal junctional superficial esophageal cancer
- no evidence of lymph node metatasis in endoscopic US, chest CT, and PET-CT
- ECOG performance status 0-2
- cT1N0
- one of those among lymphovascular invasion (+), submucosal invasion (+) or positive vertical resection margin in submucosal dissection specimen
- unresectable lesion with submucosal dissection, but patient refused to undergo curative surgery
- Informed consent

Exclusion Criteria

- Recurrent esophageal cancer
- a history of previous treatment for esophageal cancer including local or systemic therapy
- presence of other malignancies except cured skin squamous cell carcinoma, skin basal cell carcinoma and carcinoma in situ in uterine cervix.
- Uncontrolled mental illness, severe head trauma, chronic alcoholics or drug addictions

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
progression-free survival

Secondary Outcome Measures

Name	Time	Method
overall survival;Treatment-related toxicity rate